DNLI
Price
$13.95
Change
+$0.52 (+3.87%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
1.96B
34 days until earnings call
FENC
Price
$9.04
Change
+$0.34 (+3.91%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
241.9M
41 days until earnings call
Interact to see
Advertisement

DNLI vs FENC

Header iconDNLI vs FENC Comparison
Open Charts DNLI vs FENCBanner chart's image
Denali Therapeutics
Price$13.95
Change+$0.52 (+3.87%)
Volume$40.57K
Capitalization1.96B
Fennec Pharmaceuticals
Price$9.04
Change+$0.34 (+3.91%)
Volume$2.01K
Capitalization241.9M
DNLI vs FENC Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FENC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. FENC commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Buy and FENC is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (DNLI: $13.95 vs. FENC: $9.04)
Brand notoriety: DNLI and FENC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 62% vs. FENC: 75%
Market capitalization -- DNLI: $1.96B vs. FENC: $241.9M
DNLI [@Biotechnology] is valued at $1.96B. FENC’s [@Biotechnology] market capitalization is $241.9M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileFENC’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • FENC’s FA Score: 0 green, 5 red.
According to our system of comparison, FENC is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 5 TA indicator(s) are bullish while FENC’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 5 bullish, 5 bearish.
  • FENC’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, FENC is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а +9.41% price change this week, while FENC (@Biotechnology) price change was +4.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.14%. For the same industry, the average monthly price growth was +9.25%, and the average quarterly price growth was +54.64%.

Reported Earning Dates

DNLI is expected to report earnings on Oct 30, 2025.

FENC is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+4.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($1.96B) has a higher market cap than FENC($242M). FENC YTD gains are higher at: 37.658 vs. DNLI (-34.102). FENC has higher annual earnings (EBITDA): -8.39M vs. DNLI (-521.52M). DNLI has more cash in the bank: 899M vs. FENC (18.7M). FENC has less debt than DNLI: FENC (19.4M) vs DNLI (46.6M). FENC has higher revenues than DNLI: FENC (33.3M) vs DNLI (0).
DNLIFENCDNLI / FENC
Capitalization1.96B242M812%
EBITDA-521.52M-8.39M6,214%
Gain YTD-34.10237.658-91%
P/E RatioN/A60.43-
Revenue033.3M-
Total Cash899M18.7M4,807%
Total Debt46.6M19.4M240%
FUNDAMENTALS RATINGS
DNLI vs FENC: Fundamental Ratings
DNLI
FENC
OUTLOOK RATING
1..100
7257
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
88
Overvalued
PROFIT vs RISK RATING
1..100
10070
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
8746
P/E GROWTH RATING
1..100
9998
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FENC's Valuation (88) in the Biotechnology industry is in the same range as DNLI (93). This means that FENC’s stock grew similarly to DNLI’s over the last 12 months.

FENC's Profit vs Risk Rating (70) in the Biotechnology industry is in the same range as DNLI (100). This means that FENC’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (97) in the Biotechnology industry is in the same range as FENC (100). This means that DNLI’s stock grew similarly to FENC’s over the last 12 months.

FENC's Price Growth Rating (46) in the Biotechnology industry is somewhat better than the same rating for DNLI (87). This means that FENC’s stock grew somewhat faster than DNLI’s over the last 12 months.

FENC's P/E Growth Rating (98) in the Biotechnology industry is in the same range as DNLI (99). This means that FENC’s stock grew similarly to DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIFENC
RSI
ODDS (%)
Bullish Trend 2 days ago
87%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
76%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 19 days ago
77%
Bullish Trend 18 days ago
75%
Declines
ODDS (%)
Bearish Trend 12 days ago
81%
Bearish Trend 3 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
66%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FENC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CFMSX11.86N/A
N/A
Column Mid Cap Select
ECTMX17.40-0.11
-0.63%
Eaton Vance Dividend Builder C
MCVRX30.73-0.29
-0.93%
MFS Mid Cap Value R2
IJSTX13.72-0.14
-1.01%
VY® JPMorgan Small Cap Core Equity S2
BGVIX35.34-0.40
-1.12%
Brandes Global Equity I

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-0.37%
NRIX - DNLI
59%
Loosely correlated
-4.25%
OCUL - DNLI
54%
Loosely correlated
-2.55%
RGNX - DNLI
54%
Loosely correlated
-1.89%
BEAM - DNLI
54%
Loosely correlated
-2.12%
IMVT - DNLI
54%
Loosely correlated
+1.36%
More

FENC and

Correlation & Price change

A.I.dvisor indicates that over the last year, FENC has been loosely correlated with CLDX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if FENC jumps, then CLDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FENC
1D Price
Change %
FENC100%
+3.57%
CLDX - FENC
44%
Loosely correlated
-1.37%
IDYA - FENC
44%
Loosely correlated
+0.08%
DNLI - FENC
42%
Loosely correlated
-0.37%
BEAM - FENC
41%
Loosely correlated
-2.12%
ARWR - FENC
41%
Loosely correlated
-3.56%
More